
    
      Integrated Biomarker and Imaging Study -2 (IBIS-2): An International, Multicenter,
      Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and
      Imaging Study in Subjects with Angiographically Documented Coronary Heart Disease (CHD) to
      Examine the Effects of the Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2) inhibitor
      SB-480848 on Intermediate Cardiovascular Endpoints, Patient Safety and Tolerability.
    
  